Logo image of ONCR

ONCORUS INC (ONCR) Stock Fundamental Analysis

NASDAQ:ONCR - Nasdaq - US68236R1032 - Common Stock - Currency: USD

0.1206  -0.01 (-8.5%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ONCR. ONCR was compared to 571 industry peers in the Biotechnology industry. The financial health of ONCR is average, but there are quite some concerns on its profitability. ONCR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ONCR has reported negative net income.
In the past year ONCR has reported a negative cash flow from operations.
ONCR had negative earnings in each of the past 5 years.
ONCR had a negative operating cash flow in each of the past 5 years.
ONCR Yearly Net Income VS EBIT VS OCF VS FCFONCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

The profitability ratios for ONCR are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ONCR Yearly ROA, ROE, ROICONCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCR Yearly Profit, Operating, Gross MarginsONCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ONCR has more shares outstanding
Compared to 1 year ago, ONCR has a worse debt to assets ratio.
ONCR Yearly Shares OutstandingONCR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
ONCR Yearly Total Debt VS Total AssetsONCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

ONCR has an Altman-Z score of -5.89. This is a bad value and indicates that ONCR is not financially healthy and even has some risk of bankruptcy.
ONCR has a worse Altman-Z score (-5.89) than 68.01% of its industry peers.
There is no outstanding debt for ONCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.89
ROIC/WACCN/A
WACCN/A
ONCR Yearly LT Debt VS Equity VS FCFONCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

ONCR has a Current Ratio of 1.50. This is a normal value and indicates that ONCR is financially healthy and should not expect problems in meeting its short term obligations.
ONCR has a worse Current ratio (1.50) than 81.67% of its industry peers.
A Quick Ratio of 1.50 indicates that ONCR should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.50, ONCR is not doing good in the industry: 80.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
ONCR Yearly Current Assets VS Current LiabilitesONCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

ONCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.78%.
EPS 1Y (TTM)-28.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ONCR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.17% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.04%
EPS Next 2Y30.28%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCR Yearly Revenue VS EstimatesONCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 10K 20K 30K 40K
ONCR Yearly EPS VS EstimatesONCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCR. In the last year negative earnings were reported.
Also next year ONCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCR Price Earnings VS Forward Price EarningsONCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCR Per share dataONCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

ONCR's earnings are expected to grow with 21.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.28%
EPS Next 3Y21.17%

More info and screens

0

5. Dividend

5.1 Amount

ONCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCORUS INC

NASDAQ:ONCR (6/20/2023, 8:14:14 PM)

0.1206

-0.01 (-8.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-22 2023-05-22/amc
Earnings (Next)08-02 2023-08-02/bmo
Inst Owners9.11%
Inst Owner Change0%
Ins Owners11.14%
Ins Owner Change0%
Market Cap3.15M
Analysts45.71
Price Target5.1 (4128.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.88%
Min EPS beat(2)-65.27%
Max EPS beat(2)-4.49%
EPS beat(4)1
Avg EPS beat(4)-17.24%
Min EPS beat(4)-65.27%
Max EPS beat(4)1.09%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)53.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-21.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.1
EV/EBITDA N/A
EPS(TTM)-3.49
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-2.83
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS0
BVpS1.19
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 437.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z -5.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)372.13%
Cap/Depr(5y)247.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.01%
EPS Next Y34.04%
EPS Next 2Y30.28%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.81%
OCF growth 3YN/A
OCF growth 5YN/A